Patents Assigned to Janssen Pharmaceutica
  • Antibodies to olanzapine haptens and use thereof
    Patent number: 11226345
    Abstract: Disclosed is an antibody which binds to olanzapine, which can be used to detect olanzapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of olanzapine, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: January 18, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Eric Hryhorenko, Banumathi Sankaran, Thomas R. DeCory, Theresa Tubbs, Linda Colt, Bart M. Remmerie, Rhys Salter, Matthew Garrett Donahue, Yong Gong
  • Spiro bicyclic inhibitors of menin-MLL interaction
    Patent number: 11220517
    Abstract: The present invention relates to compounds of formula (I): wherein the variables have the meaning defined in the Specification. The compounds according to the present invention are useful for therapy and/or prophylaxis in a mammal, and in particular to spiro bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: January 11, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Patrick Rene Angibaud, Vineet Pande, Barbara Herkert, Daniel Jason Krosky, Olivier Alexis Georges Querolle, Aaron Nathaniel Patrick, Isabelle Noelle Constance Pilatte
  • Substituted pyridine derivatives useful as C-FMS kinase inhibitors
    Patent number: 11214566
    Abstract: The present invention is directed to substituted pyridine derivatives, pharmaceutical compositions containing said derivatives and the use of said derivatives in the treatment of disorders mediated by c-fms kinase. The present invention is further directed to a process for the preparation of said substituted pyridine derivatives.
    Type: Grant
    Filed: September 2, 2020
    Date of Patent: January 4, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Jie Chen, Matthew Donahue, Heng-Keang Lim, Ronghui Lin, Rhys Salter, Jiejun Wu, Yong Gong
  • Substituted pyrazolo-pyrazines and their use as GluN2B receptor modulators
    Patent number: 11214563
    Abstract: Substituted PYRAZOLO-PYRAZINES as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: January 4, 2022
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Curt Dvorak, Heather Coate
  • Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
    Patent number: 11207337
    Abstract: The present invention is directed to the use of co-therapy comprising administration of canagliflozin and phentermine for the treatment of obesity and obesity related disorders. More particularly, the present invention is directed to co-therapy for treating obesity, for promoting weight loss and/or for suppressing appetite; for treating, delaying, slowing the progression of and/or preventing metabolic disorders (including for example Type 2 diabetes mellitus); for treating, delaying, slowing the progression of and/or preventing renal or fatty liver disorders (including for example NASH, NAFLD, etc.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: December 28, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Norman R. Rosenthal, Paul Rothenberg, David C. Polidori, Douglas K. Ways, Peter P. Stein
  • Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators
    Patent number: 11207298
    Abstract: Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.
    Type: Grant
    Filed: March 3, 2020
    Date of Patent: December 28, 2021
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Christa C. Chrovian, Michael A. Letavic, Jason C. Rech, Dale A. Rudolph, Akinola Soyode-Johnson, Brice M. Stenne, Jessica L. Wall
  • Method of treating prostate cancer
    Patent number: 11207311
    Abstract: Disclosed are methods of treating prostate cancer by administering niraparib to a human in need thereof.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: December 28, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Marco Gottardis, Rebecca Hawkins, Linda A Snyder, Douglas H Yamada
  • Cyanoindoline derivatives as NIK inhibitors
    Patent number: 11186589
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: November 30, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Ian Stansfield, Olivier Alexis Georges Querolle, Yannick Aime Eddy Ligny, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel, Simon Richard Green, George Hynd, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann
  • Substituted cyanoindoline derivatives as NIK inhibitors
    Patent number: 11180487
    Abstract: The present invention relates to pharmaceutical agents of formula (I) useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: November 23, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Ian Stansfield, Olivier Alexis Georges Querolle, Virginie Sophie Poncelet, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann, Simon Richard Green, George Hynd
  • Biological markers for identifying patients for treatment with abiraterone acetate
    Patent number: 11180809
    Abstract: Provided herein are methods of predicting a likelihood of survival following treatment with AA and prednisone in a patient having CRPC.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: November 23, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Deborah Sokol Ricci, Weimin Li, Michael Gormley, Jayaprakash Karkera, Michael Schaffer
  • Methods for the treatment of depression
    Patent number: 11173134
    Abstract: The present invention is directed to methods and dosing regimens for the treatment of depression (preferably, treatment resistant depression), for the treatment of depression in a suicidal patient, and/or for the treatment and/or prevention of suicidality (e.g. suicidal ideations).
    Type: Grant
    Filed: December 21, 2020
    Date of Patent: November 16, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Lodewijk Ivo Caers, Jaskaran Singh, Peter Nicholas Zannikos, Wayne C. Drevets, Ella Daly, Carla Marie Canuso, Margaret Fedgchin, Frank Wiegand
  • Tau PET imaging ligands
    Patent number: 11168068
    Abstract: The present invention relates to novel, selective radiolabelled tau ligands which are useful for imaging and quantifying tau aggregates, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue or a subject, in vitro or in vivo, and to precursors of said compounds.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: November 9, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: José Ignacio Andrés-Gil, Guy Maurits R. Bormans, Lieven Denis Herwig Declercq, Katleen Fierens, Joseph Elisabeth Leenaerts, Diederik Willem Elisabeth Moechars, Frederik Jan Rita Rombouts, Hartmuth Kolb, Wei Zhang
  • Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators
    Patent number: 11161846
    Abstract: Substituted pyrazolo[4,3-b]pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: November 2, 2021
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Afton Hiscox, Brice Stenne, Christine Gelin, Andrew Samant, Jessica Wall, Michael A. Letavic, Curt Dvorak
  • Compounds
    Patent number: 11155555
    Abstract: The invention relates to new quinoxaline, quinoline and quinazolinone derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: October 26, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Patrick Rene Angibaud, Diego Fernando Domenico Broggini, Helene France Solange Colombel, Filip Albert C Cuyckens, Steven Anna Hostyn, Russell Mark Jones, Olivier Alexis Georges Querolle, Wim Vermeulen
  • Long-acting formulations
    Patent number: 11141384
    Abstract: This invention concerns pharmaceutical compositions for administration via intramuscular or subcutaneous injection, comprising micro- or nanoparticles of the anti-TB compound bedaquiline, suspended in an aqueous pharmaceutically acceptable carrier, and the use of such pharmaceutical compositions in the treatment and prophylaxis of a pathogenic mycobacterial infection.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: October 12, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Koenraad Jozef Lodewijk Marcel Andries, Maristella Bernini, Esther Dina Guido Basstanie
  • Heteroaromatic derivatives as NIK inhibitors
    Patent number: 11136311
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: October 5, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Ian Stansfield, Olivier Alexis Georges Querolle, Yannick Aime Eddy Ligny, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel, Simon Richard Green, George Hynd, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann
  • Quinoxaline and pyridopyrazine derivatives as PI3K-beta inhibitors
    Patent number: 11130751
    Abstract: The present invention relates to substituted quinoxaline and pyridopyrazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3K? inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: September 28, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Patrick René Angibaud, Olivier Alexis Georges Querolle, Didier Jean-Claude Berthelot, Christophe Meyer, Matthieu Philippe Victor Willot, Lieven Meerpoel, Thierry François Alain Jean Jousseaume
  • AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS
    Publication number: 20210284641
    Abstract: Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compounds of Formula (I).
    Type: Application
    Filed: May 19, 2021
    Publication date: September 16, 2021
    Applicant: Janssen Pharmaceutica NV
    Inventors: Michael K. Ameriks, Cynthia G.B. Berry, Gang Chen, Fabrice Loic Jourdan, Terry Patrick Lebold, David Wei Lin, Miguel Angel Pena Piñon, Suohitra Ravula, Bradley M. Savall, Devin M. Swanson, Dongpei Wu, Wei Zhang
  • Antibodies to quetiapine and use thereof
    Patent number: 11104742
    Abstract: Disclosed is an antibody or a binding fragment thereof which binds to quetiapine, which can be used to detect quetiapine in a sample such as in a competitive immunoassay method. The antibody or the fragment thereof can be used in a lateral flow assay device for point-of-care detection of quetiapine, including multiplex detection of aripiprazole, quetiapine, olanzapine, and risperidone in a single lateral flow assay device.
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: August 31, 2021
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Eric Hryhorenko, Banumathi Sankaran, Thomas R. DeCory, Theresa Tubbs, Linda Colt, Bart M. Remmerie, Rhys Salter, Matthew G. Donahue, Yong Gong
  • Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
    Patent number: RE48841
    Abstract: Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: December 7, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Wenying Chai, Michael A. Letavic, Kiev S. Ly, Daniel J. Pippel, Dale A. Rudolph, Kathleen C. Sappey, Brad M. Savall, Chandravadan R. Shah, Brock T. Shireman, Akinola Soyode-Johnson, Emily M. Stocking, Devin M. Swanson